Biography:
John M. York, Pharm.D., MBA, Ph.D.c is at Texas Christian University, Burnett School of Medicine as an assistant clinical professor of medical education; University of California, San Diego, as a visiting professor of practice and co-director of the translational medicine capstone project and lead instructor at the Institute for the Global Entrepreneur. He also serves as faculty at Rutgers's Ernest Mario School of Pharmacy, overseeing scholarly projects within the industry post-doc program. York's oncology experience spans over 30 years, including efforts at Amgen, HDI, and Akita Biomedical. His activities include being an associate editor for Cancer Control from 2008-2018 and collaborating with the H Lee Moffitt Cancer Center in Tampa, FL. He has over 45 peer-reviewed articles on clinical translations, pharmacoeconomics, entrepreneurship, and management topics. His oncology consulting includes work with Celgene, Daiichi Sankyo, Genentech, HRA Pharma, Novartis, Pharmion, and Pfizer.
Preclinical evaluation of CLX-155A, a novel prodrug conjugate of 5-FU and valproic acid, for triple-negative breast cancer
Preclinical evaluation of CLX-155A, a novel prodrug conjugate of 5-FU and valproic acid, to assess activity in a Foxn1 athymic nude mouse colorectal cancer model
Preclinical evaluation of CLX-155, a novel prodrug o 5-FU for the treatment of cancer